Qiagen NV
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.9 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 86.57% +4.86pp
- Institutions
- 555 +13
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-11-05
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
5 filings tracked · 0 buys · 5 sells
| Name | Role | Stake |
|---|---|---|
| Thierry Bernard | Former CEO, MD & Member of Management Board | 0.21% |
| Roland Sackers | CFO, MD & Member of Management Board | 0.19% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2025-08-14 | Roland Sackers | CFO, MD & Member of Management Board | Intent to Sell (Form 144) | -29,851 | $51.80 |
| 2025-08-14 | Thierry Bernard | Former CEO, MD & Member of Management Board | Intent to Sell (Form 144) | -23,750 | $51.37 |
| 2025-08-13 | Roland Sackers | CFO, MD & Member of Management Board | Intent to Sell (Form 144) | -17,648 | $51.58 |
| 2025-08-12 | Roland Sackers | CFO, MD & Member of Management Board | Intent to Sell (Form 144) | -47,500 | $51.71 |
| 2024-09-10 | Roland Sackers | CFO, MD & Member of Management Board | Intent to Sell (Form 144) | -23,090 | $49.80 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Qiagen NV discussion 0 comments